Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry.  We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what developments in drug testing mean for the future of genetic research.  A big thank you to all our guests that featured in this series, make sure you show your appreciation to our esteemed guests by re-listening to your favorite episode and subscribing to Invent: Life Sciences from wherever you get your podcasts.  And finally, a big t ..read more

Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increased focus on the means by which processes and products themselves are characterised. So, do current process analytical tools provide the insights therapy developers need? And how can new technologies be implemented in the fast-moving life sciences field? To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product ..read more

Across the life sciences industry, there is much excitement over the potential impact of stem cells in medicine. And it is clear why; these cells, which can be differentiated into any other cell type, could rewrite the playbook in terms of sourcing cellular material for advanced therapies manufacture. So how might therapy developers benefit from the unique abilities of stem cells? And will they live up to their expectations? To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. This Week's Guests Marinna Madrid Marinna Madri ..read more

Throughout almost all of medical history, it was assumed that the average white male response to drug trials could be extrapolated to all potential recipients. But when we look at the poorer health outcomes for women and minorities, could the underlying assumptions in medical research be a contributing factor? If so, what is being done to solve them? To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. This Week's Guests Diana Torgersen Diana Torgersen is the Executive Director for External Innovation & Emerging Scienc ..read more

Pharmaceutical companies undertake rigorous clinical trials in order to find out which drugs are safe. But in order to better protect the people volunteering for these tests, regulators decreed that data from studies on animals would be the primary evidence needed before approving a clinical trial in humans. Testing drugs on animals has many ethical and practical issues, and so scientists are looking towards different types of in-vitro models as a solution. But what are these models? How can they move us towards safer, better trials? To find out, join us on Invent: Life Sciences, a podcast br ..read more

Modern medicine has helped us develop many effective treatments for diseases found throughout the body, but we’ve yet to have the same success with the brain. The so-called 'blood brain barrier' controls the passage of molecules out of the blood and into the brain, and so it’s not as easy to use the bloodstream to carry therapeutic molecules as we might do for other diseases. Could the blood brain barrier be the key to treating neurological disorders? How can we target this structure to make therapies more effective? To find out, join us on Invent: Life Sciences, a podcast brought to you by t ..read more

In the pharmaceutical industry, there is a desire to go beyond the traditional ‘compound x acts on protein y,’ and achieve a more nuanced effect on the underlying biology. So, could innovative approaches to small molecules open up a wider application space? And what benefits might this bring to cash-strapped healthcare systems? To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. This Week's Guests Anne Horgan Anne Horgan is a partner at Cambridge Innovation Captial, a venture capital firm that invest in IP rich businesses ..read more

Cell and gene therapies are extremely effective but their complex production processes, arduous supply chain, and life-critical logistics have prevented mass market adoption. Could digitisation and AI provide a breakthrough in manufacturing? Would more companies be willing to work together on standardisation to provide more flexibility? To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. This Week's Guests Matthew Durdy Matthew Durdy is a biologist, investor, entrepreneur, and the Chief Executive of the Cell and Therapy C ..read more

The Covid vaccination campaign demonstrated the effectiveness of mRNA-based treatments, so what else is this technology capable of? How can we improve our manufacturing and distribution to ensure treatments are available to those who need them most?   To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. What is mRNA and what is the importance of mRNA treatments? Messenger ribonucleic acid, or mRNA for short, is a crucial molecule in the process of making proteins in our bodies. Proteins are essential for the structure ..read more

Invent: Life Sciences is back for Season 2!  Invent: Life Sciences is a podcast about the future of life science and technology, hosted by Head of Cell Gene Therapy and Biotechnology at TTP, Stuart Lowe. Each episode, we’ll be joined by the top scientists, designers, business leaders, and academics working at the vanguard of this vital industry, to give you a behind-the-scenes look at the world of life science. In this new season, we now turn our focus onto advances driving forward the pharmaceutical sector, and how life scientists are dedicating their lives to bringing the benefits of me ..read more